Figure 3

Kaplan-Meier survival curve and log-rank test for NPC patients classified as showing either high or low SPARC expression. (A) Kaplan-Meier curve for 5-year overall survival rate (69.1%) of 1093 patients with NPC; (B) Overall survival curve of NPC patients with different SPARC expression and the 5-year OS rate was significantly different between NPC patients with low expression (74.9%) and high expression (58.9%) (P < 0.001; log-rank test); (C) Cases stratified by clinical stage. Within the early stage (Stage I + II) stratum, SPARC expression did not show a statistical (P = 0.256; log-rank test) relationship with patients survival; (D) Within the advanced stage (Stage III + IV) stratum, SPARC expression exhibited a significant (P < 0.001; log-rank test) relationship with patients survival.